Market Closed -
Nasdaq
21:00:00 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
19.83
USD
|
-8.02%
|
|
-2.27%
|
-12.37%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
287.8
|
720.9
|
626.1
|
569.9
|
-
|
-
|
Enterprise Value (EV)
1 |
233.6
|
591.7
|
626.1
|
506.8
|
576.7
|
569.9
|
P/E ratio
|
-6.3
x
|
-14
x
|
-7.89
x
|
-6.49
x
|
-6.41
x
|
-6.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
126
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
126
x
|
EV / EBITDA
|
-
|
-11,128,828
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8.47
x
|
-15
x
|
-
|
-6.26
x
|
-6.67
x
|
-8.08
x
|
FCF Yield
|
-11.8%
|
-6.64%
|
-
|
-16%
|
-15%
|
-12.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
24,410
|
24,605
|
27,669
|
28,737
|
-
|
-
|
Reference price
2 |
11.79
|
29.30
|
22.63
|
19.83
|
19.83
|
19.83
|
Announcement Date
|
30/03/22
|
29/03/23
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
4.52
|
EBITDA
|
-
|
-
|
-53.17
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-23.02
|
-53.24
|
-81.41
|
-92.49
|
-102.5
|
-106.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,360.04%
|
Earnings before Tax (EBT)
1 |
-
|
-22.96
|
-51.49
|
-75.46
|
-88.32
|
-99.24
|
-103.2
|
Net income
1 |
-9.611
|
-22.96
|
-51.51
|
-75.52
|
-89.04
|
-99.56
|
-103.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,284.93%
|
EPS
2 |
-40.32
|
-1.870
|
-2.100
|
-2.870
|
-3.054
|
-3.096
|
-2.968
|
Free Cash Flow
1 |
-
|
-27.58
|
-39.32
|
-
|
-81
|
-86.5
|
-70.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,559.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/05/21
|
30/03/22
|
29/03/23
|
25/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.2
|
-8.268
|
-11.02
|
-12.22
|
-14.15
|
-15.85
|
-17.64
|
-20.34
|
-21.37
|
-22.07
|
-22.22
|
-22.75
|
-23.32
|
-23.92
|
-26.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.184
|
-8.22
|
-10.91
|
-11.99
|
-13.59
|
-15
|
-16.52
|
-19.02
|
-19.56
|
-20.36
|
-21.09
|
-21.65
|
-22.27
|
-22.9
|
-24.3
|
Net income
1 |
-6.184
|
-8.223
|
-10.91
|
-11.99
|
-13.59
|
-15.02
|
-16.52
|
-19.02
|
-19.56
|
-20.41
|
-21.37
|
-21.91
|
-22.49
|
-23.09
|
-24.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2600
|
-0.0700
|
-0.4500
|
-0.4900
|
-0.5600
|
-0.6100
|
-0.6700
|
-0.7600
|
-0.7100
|
-0.7400
|
-0.7650
|
-0.7500
|
-0.7483
|
-0.7617
|
-0.6800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
30/03/22
|
16/05/22
|
15/08/22
|
14/11/22
|
29/03/23
|
15/05/23
|
14/08/23
|
13/11/23
|
25/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
6.79
|
-
|
Net Cash position
1 |
-
|
54.2
|
129
|
-
|
63.1
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-27.6
|
-39.3
|
-
|
-81
|
-86.5
|
-70.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.18
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/05/21
|
30/03/22
|
29/03/23
|
25/03/24
|
-
|
-
|
-
|
Last Close Price
19.83
USD Average target price
44.67
USD Spread / Average Target +125.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.37% | 570M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +46.68% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|